Immune checkpoint inhibitors enhanced the antitumor efficacy of disitamab vedotin for patients with HER2-positive or HER2-low advanced or metastatic gastric cancer: a multicenter real-world study

Table 2 Efficacy of RC48 in patients with advanced or metastatic gastric cancer

Parameter	Best response				ORR	P	DCR	P	Median PFS (95%CI)	P
Parameter	CR	PR	SD	PD	ORR	P	DCR	P	Median PFS (95%CI)	P
Total	0	11	19	15	24.4%		66.7%		4.9(2.8-7.0)
Treatment programs						0.044		0.034		0.140
RC48	0	2	8	10	10.0%		50.0%		3.9(0.3–7.5)
RC48 + ICIs	0	9	11	5	36.0%		80.0%		6.2(2.3–10.1)
HER-2 status						0.464		1.000		0.299
Positive	0	9	13	11	27.3%		66.7%		5.7(3.1–8.3)
HER2-low	0	2	6	4	16.7%		66.7%		4.3(1.3–7.3)

Abbreviations: CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, overall response rate; DCR, disease control rate; PFS, progression free survival; OS, overall survival; ICIs, immune checkpoint inhibitors.

ISSN: 1471-2407